Published on 15 Oct 2022 on Simply Wall St. via Yahoo Finance

ThermoGenesis Holdings, Inc. (NASDAQ:THMO): Are Analysts Optimistic?

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. The US$8.0m market-cap company’s loss lessened since it announced a US$11m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$9.0m, as it approaches breakeven. As path to profitability is the topic on ThermoGenesis Holdings' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

See our latest analysis for ThermoGenesis Holdings

ThermoGenesis Holdings is bordering on breakeven, according to some American Medical Equipment analysts. They expect the company to post a final loss in 2023, before turning a profit of US$2.3m in 2024. The company is therefore projected to breakeven around 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2024? Working backwards from analyst estimates, it turns out that they expect the company to grow 67% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.